Adelaide, Australia, 30th March 2023 - GPN Vaccines Ltd is pleased to announce that dose escalation has been approved and dosing of the second cohort has commenced in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial is assessing the...
GPN Vaccines was initially established with the goal of creating a vaccine capable of protecting children and adults against all serotypes of Streptococcus pneumoniae (the pneumococcus), a deadly pathogen responsible for killing up to two million people worldwide each year. Such a vaccine represents the...
Adelaide, Australia, 16th January 2023 GPN Vaccines Ltd is pleased to announce that the first participant has been dosed in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial will assess the safety, tolerability and immunogenicity of Gamma-PN. One hundred...
Adelaide, Australia, 20th October 2022 - Professor Tim Hirst, GPN Vaccines’ Chairman and CEO, has been awarded Angel of the Year by Techboard, in recognition of his contribution to angel investment and his overall positive impact on the angel community. Tim commented, "I'm honoured to have been nominated by...
Adelaide, Australia, 21st September 2022 - GPN Vaccines is pleased to announce publication of a landmark scientific paper in the prestigious journal mBio showing its novel pneumococcal vaccine, Gamma-PN, elicits a broad-spectrum, serotype-independent opsonophagocytic antibody response. This research, conducted in collaboration with the University of Adelaide,...